Source comparison
BPC-157 for MS Research: Comparison Across Study Models and Administration Routes
EAE (C57BL/6 mice, MOG-induced) Intraperitoneal injection 10 mcg/kg daily, therapeutic (post-onset) Clinical score, lesion volume, cytokine profile 38% vs saline control Moderate (score reduced by 1.5 points on 5-point scale) VEGF upregulation, TNF-alpha suppr
This comparison does not assign a generated winner or score.
- EAE (C57BL/6 mice, MOG-induced)
- Intraperitoneal injection
- 10 mcg/kg daily, therapeutic (post-onset)
- Clinical score, lesion volume, cytokine profile
- 38% vs saline control
- Moderate (score reduced by 1.5 points on 5-point scale)
- VEGF upregulation, TNF-alpha suppression
- EAE (Lewis rats, MBP-induced)
- Subcutaneous injection
- 5 mcg/kg daily, prophylactic (pre-onset)
- Blood-brain barrier permeability, axonal density
- 22% vs control
- Mild (delayed onset by 3 days)
- Blood-brain barrier stabilization, reduced leukocyte infiltration
- Oral gavage
- 50 mcg/kg daily, therapeutic
- Clinical score, microglial activation markers
- 15% vs control
- Minimal (non-significant)
- Microglial M1/M2 polarization shift
- In vitro oligodendrocyte culture (cuprizone model)
- Culture medium (direct exposure)
- 1–10 micromolar concentration
- Oligodendrocyte survival, myelin protein expression
- N/A (culture model)
- N/A
- Oligodendrocyte differentiation support, oxidative stress reduction
- Intraperitoneal and subcutaneous routes consistently show stronger effects than oral administration, likely due to peptide degradation in the GI tract. The highest lesion volume reductions occur with therapeutic dosing at disease peak, not prophylactic administration. Suggesting BPC-157 may act on active inflammation rather than preventing disease induction. The in vitro data indicates direct neuroprotective effects independent of immune modulation, which is relevant because MS pathology includes both immune-mediated damage and primary oligodendrocyte dysfunction.